statistiche ricercatore

PASSAMONTI, FRANCESCO

Distribuzione geografica

Continente	#
NA - Nord America	28.346
EU - Europa	10.773
AS - Asia	7.404
SA - Sud America	946
Continente sconosciuto - Info sul continente non disponibili	551
AF - Africa	105
OC - Oceania	7
Totale	48.132

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	27.998
IT - Italia	5.800
SG - Singapore	2.235
CN - Cina	1.686
UA - Ucraina	1.568
TR - Turchia	1.032
VN - Vietnam	1.026
HK - Hong Kong	769
BR - Brasile	753
SE - Svezia	703
IE - Irlanda	613
DE - Germania	426
GB - Regno Unito	426
FI - Finlandia	350
FR - Francia	331
RU - Federazione Russa	260
BD - Bangladesh	215
CA - Canada	186
IN - India	92
MX - Messico	77
AR - Argentina	69
JP - Giappone	67
PK - Pakistan	49
NL - Olanda	46
CZ - Repubblica Ceca	41
ES - Italia	39
AT - Austria	37
PL - Polonia	37
EC - Ecuador	35
IQ - Iraq	34
ID - Indonesia	28
ZA - Sudafrica	28
SA - Arabia Saudita	23
CO - Colombia	22
VE - Venezuela	22
CR - Costa Rica	21
UZ - Uzbekistan	19
HN - Honduras	18
MY - Malesia	18
JM - Giamaica	15
LT - Lituania	15
BE - Belgio	14
CL - Cile	13
KR - Corea	12
NG - Nigeria	12
AE - Emirati Arabi Uniti	11
EG - Egitto	11
EU - Europa	11
JO - Giordania	11
MA - Marocco	11
DZ - Algeria	10
PY - Paraguay	10
HU - Ungheria	9
KE - Kenya	9
NP - Nepal	9
PE - Perù	9
CH - Svizzera	8
IR - Iran	8
BG - Bulgaria	7
ET - Etiopia	7
IL - Israele	7
KZ - Kazakistan	7
LB - Libano	7
PH - Filippine	7
TW - Taiwan	7
UY - Uruguay	7
MD - Moldavia	6
NO - Norvegia	6
OM - Oman	6
RS - Serbia	6
TH - Thailandia	6
GT - Guatemala	5
SN - Senegal	5
TN - Tunisia	5
AU - Australia	4
AZ - Azerbaigian	4
BA - Bosnia-Erzegovina	4
RO - Romania	4
TT - Trinidad e Tobago	4
AL - Albania	3
BO - Bolivia	3
BS - Bahamas	3
DO - Repubblica Dominicana	3
GR - Grecia	3
NZ - Nuova Zelanda	3
PR - Porto Rico	3
AO - Angola	2
DK - Danimarca	2
EE - Estonia	2
GP - Guadalupe	2
GY - Guiana	2
KW - Kuwait	2
LU - Lussemburgo	2
NI - Nicaragua	2
PA - Panama	2
PS - Palestinian Territory	2
PT - Portogallo	2
SK - Slovacchia (Repubblica Slovacca)	2
TC - Turks e Caicos	2
XK - ???statistics.table.value.countryCode.XK???	2
Totale	47.577

Salva come PNG Salva come JPEG

Città	#
Milan	4.237
Fairfield	3.291
Woodbridge	2.769
Ashburn	2.517
Houston	2.085
San Jose	1.901
Ann Arbor	1.578
Seattle	1.345
Jacksonville	1.338
Cambridge	1.177
Singapore	1.134
Wilmington	1.128
Hong Kong	754
Chandler	678
Dallas	643
Dublin	610
Council Bluffs	552
Princeton	526
Dearborn	479
Izmir	473
Nyköping	365
Boardman	337
The Dalles	317
Beijing	312
Dong Ket	271
Rome	265
Lauterbourg	235
Los Angeles	181
San Diego	178
New York	171
Santa Clara	162
Ho Chi Minh City	160
Ogden	133
Hanoi	125
London	100
Chicago	94
Como	84
Guangzhou	81
Washington	71
Redmond	67
São Paulo	67
Orem	62
Helsinki	61
Atlanta	57
Phoenix	56
San Francisco	56
Mexico City	55
Hefei	54
Montreal	50
Tokyo	50
Waltham	49
Kocaeli	48
Brooklyn	47
Denver	47
Toronto	47
Nanjing	45
Hangzhou	44
Munich	44
Shanghai	41
Kunming	37
Zhengzhou	36
Warsaw	32
Tianjin	31
Da Nang	30
Norwalk	30
Salt Lake City	30
Brno	29
Kilburn	29
Rio de Janeiro	29
Columbus	28
Boston	27
Frankfurt am Main	27
Nuremberg	27
Redwood City	25
Jinan	24
Chennai	23
Nanchang	23
Düsseldorf	21
Las Vegas	21
Haiphong	20
Ankara	19
Manchester	19
Buffalo	18
Changsha	18
Johannesburg	18
Memphis	18
Miami	18
Quito	18
Tashkent	18
Belo Horizonte	17
Brasília	17
Rawalpindi	17
Verona	17
Amsterdam	16
Dhaka	16
Philadelphia	16
Poplar	16
Stockholm	16
Turku	16
Vienna	16
Totale	34.827

Salva come PNG Salva come JPEG

Nome	#
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients	827
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations	544
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm	295
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.	291
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence	288
A gain-of-function mutation of JAK2 in myeloproliferative disorders	280
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs	276
Analysis of three screening methods for the detection of calreticulin gene mutations	275
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial	274
European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.	260
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group	257
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis	255
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts	254
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN	253
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations	249
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study	249
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.	246
Mutations and thrombosis in essential thrombocythemia: Prognostic interaction with age and thrombosis history	246
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis	245
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.	241
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT.	239
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms	238
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.	237
Mutational status of myeloproliferative neoplasms.	237
New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma	237
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.	235
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients	233
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group	231
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia	227
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera	227
Looking for CALR mutations in familial myeloproliferative neoplasms	227
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients	226
A novel germline JAK2 mutation in familial myeloproliferative neoplasms	225
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA	225
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion	224
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.	221
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons	221
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients	220
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis	219
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies	218
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms	218
TREATMENT OF POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PIPOBROMAN.	217
A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT.	216
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia.	216
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis	214
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts	214
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia	213
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report	212
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera.	211
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders	211
It is time to change thrombosis risk assessment for PV and ET?	209
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)	209
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders	208
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.	208
Standard care and investigational drugs in the treatment of myelofibrosis	208
Novel agents in indolent lymphomas	207
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients.	206
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis: Haematologica 2012;97(3):360-5 - Comment	206
What are RBC-transfusion-dependence and -independence?	205
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)	205
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.	205
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis	205
Developments in diagnosis and treatment of essential thrombocythemia	205
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project	204
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group	204
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early /prefibrotic primary myelofibrosis.	202
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.	202
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia	202
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients	202
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases	201
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2	201
Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients	201
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.	200
Disease anticipation in familial myeloproliferative neoplasms.	200
To the editor: In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology	200
Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma	200
Direct-Acting Antivirals During or After Immunochemotherapy in Hepatitis C Virus-Positive Diffuse Large B-Cell Lymphomas	200
Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis	200
Role of the molecular staging and response in the management of follicular lymphoma patients	199
A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients	199
Cardiovascular events and intensity of treatment in polycythemia vera	198
How I treat polycythemia vera	198
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group	198
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.	197
JAK inhibitor in CALR-mutant myelofibrosis	197
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms.	196
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis	196
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis	196
RBC-transfusion guidelines update	194
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process	194
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study	194
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub	194
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy	193
Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden	192
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment	191
Blast phase of essential thrombocythemia: A single center study.	191
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.	190
New generation small-molecule inhibitors in myeloproliferative neoplasms	190
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project	190
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)	189
Totale	22.795

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	191.388
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	191.388

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	1.792	0	0	0	118	96	128	150	159	146	416	243	336
2022/2023	2.444	283	79	141	230	177	650	15	300	372	82	40	75
2023/2024	6.571	1.015	1.045	1.030	1.308	1.278	449	66	83	201	20	24	52
2024/2025	3.136	26	12	606	106	104	251	107	217	389	241	246	831
2025/2026	9.211	591	535	640	1.179	557	496	1.744	696	1.287	675	432	379
2026/2027	3.917	1.106	963	1.542	306	0	0	0	0	0	0	0	0
Totale													48.132